Seattle biotech scores $67.5M to treat migraines and Parkinson’s with drugs delivered deep into the nasal cavity Seattle-based biotech firm Impel NeuroPharma closed its latest round of funding, bringing in $67.5 million to develop treatments for central… Read More
